CRP and osteosarcoma: Next to urological cancers, systemic inflammatory markers have been evaluated in multiple other malignancies: For example, a recent meta-analysis showed high levels of NLR, GPS and CRP to be associated with worsened prognosis in patients with osteosarcoma (Song et al. 2021).